Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial

Crit Care Med. 2005 Oct;33(10):2426-8. doi: 10.1097/01.ccm.0000183002.26587.ff.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Anti-Infective Agents / adverse effects*
  • Anti-Infective Agents / therapeutic use
  • Drug Approval
  • Hemorrhage / chemically induced*
  • Humans
  • Product Surveillance, Postmarketing
  • Protein C / adverse effects*
  • Protein C / therapeutic use
  • Randomized Controlled Trials as Topic
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Sepsis / drug therapy*
  • United States

Substances

  • Anti-Infective Agents
  • Protein C
  • Recombinant Proteins
  • drotrecogin alfa activated